You can buy or sell TRIL and other stocks, options, ETFs, and crypto commission-free!
Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the development of therapies for the treatment of cancer. Read More Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
52 Week High
52 Week Low
Yahoo FinanceMay 13
Trillium: 1Q Earnings Snapshot
MISSISSAUGA, Ontario (AP) _ Trillium Therapeutics Inc. (TRIL) on Monday reported a loss of $8 million in its first quarter. On a per-share basis, the Mississauga, Ontario-based company said it had a loss of 46 cents. The company's shares closed at 59 cents. A year ago, they were trading at $6.60. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TRIL at https://www.zacks.com/ap/TRIL...
Associated PressApr 30
Trillium Announces Management and Board Changes and Provides Corporate Update
TORONTO, April 30, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive management team, its board of directors and provides an operational update. Corporate Governance Changes Niclas Stiernholm, Ph.D., has informed the Board of Directors of his resignation as President & Chief Executive Officer of the Company effective Ap...
-$0.91 per share
-$0.61 per share